litlas
Log inCreate account

Atul Deodhar

Active 1994–2025

159
Papers
18,232
Citations
76
h-index
145
i10-index

Citations

Citations per year for Atul Deodhar1986: 1 citations1995: 1 citations1996: 3 citations1997: 1 citations1999: 3 citations2000: 8 citations2001: 7 citations2002: 4 citations2003: 5 citations2004: 6 citations2005: 9 citations2006: 4 citations2007: 2 citations2008: 7 citations2009: 23 citations2010: 24 citations2011: 48 citations2012: 34 citations2013: 43 citations2014: 53 citations2015: 85 citations2016: 104 citations2017: 133 citations2018: 168 citations2019: 637 citations2020: 956 citations2021: 939 citations2022: 759 citations2023: 567 citations2024: 938 citations2025: 398 citations2026: 5 citations1987–1994: no citations, so these years are not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,208 citing papers, 17% of this breakdownUnited Kingdom: 643 citing papers, 9.1% of this breakdownGermany: 518 citing papers, 7.3% of this breakdownCanada: 413 citing papers, 5.8% of this breakdownChina: 395 citing papers, 5.6% of this breakdownFrance: 339 citing papers, 4.8% of this breakdownItaly: 337 citing papers, 4.8% of this breakdownNetherlands: 335 citing papers, 4.7% of this breakdownSpain: 255 citing papers, 3.6% of this breakdownSwitzerland: 232 citing papers, 3.3% of this breakdownBelgium: 207 citing papers, 2.9% of this breakdownJapan: 178 citing papers, 2.5% of this breakdown
0%17%Other 28.6%

Institutions

Fields

  • Medicine74.9%
  • Immunology and Microbiology17.3%
  • Biochemistry, Genetics and Molecular Biology5.2%
  • Neuroscience0.4%
  • Nursing0.3%
  • Health Professions0.3%
  • Other1.6%

Topics

  • Spondyloarthritis Studies and Treatments18.3%
  • Rheumatoid Arthritis Research and Therapies14.7%
  • Psoriasis: Treatment and Pathogenesis12.2%
  • Autoimmune and Inflammatory Disorders Research5.4%
  • Spine and Intervertebral Disc Pathology2.7%
  • Dermatology and Skin Diseases2.5%
  • Other44.2%

Coauthors

All papers

Open in search
  1. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    Authors: Gerd R Burmester, Stanley Cohen, Kevin Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman‐Yassky - RMD Open 2023 cited by 210

  2. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

    Authors: Michael M. Ward, Atul Deodhar, Lianne S. Gensler, Maureen Dubreuil, David Tak Yan Yu, Muhammad Asim Khan, Nigil Haroon, David Borenstein, Runsheng Wang, Ann Biehl, Meika A. Fang, Grant H. Louie, Vikas Majithia, Bernard Ng, Rosemary Bigham, Michael Pianin, Amit Shah, Nancy Sullivan, Marat Turgunbaev, Jeff Oristaglio, Amy S. Turner, Walter P. Maksymowych, Liron Caplan - Arthritis & Rheumatology 2019 cited by 692

  3. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

    Authors: Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson, Shephard Mpofu, Hanno B. Richards - New England Journal of Medicine 2015 cited by 1,003

  4. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

    Authors: Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee - Annals of the Rheumatic Diseases 2022 cited by 204

  5. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

    Authors: Désirée van der Heijde, In-Ho Song, Aileen L. Pangan, Atul Deodhar, Filip Van den Bosch, Walter P. Maksymowych, Tae‐Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui, Xin Wang, Alvina D. Chu, Joachim Sieper - The Lancet 2019 cited by 346

  6. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

    Authors: Atul Deodhar, Philip Helliwell, Wolf‐­Henning Boehncke, Alexa P. Kollmeier, Elizabeth C. Hsia, Ramanand A. Subramanian, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Christopher T Ritchlin - The Lancet 2020 cited by 322

  7. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

    Authors: Atul Deodhar, Paula Śliwińska-Stańczyk, Huji Xu, Xenofon Baraliakos, Lianne S. Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S. Kanik, Désirée van der Heijde - Annals of the Rheumatic Diseases 2021 cited by 248

  8. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In‐Ho Song - The Lancet 2022 cited by 135

  9. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

    Authors: Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, Dafna D. Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M. Elaine Husni, Sarah Kenny, Jennifer Kwan‐Morley, Janice Lin, Paula Marchetta, Philip J. Mease, Joseph F. Merola, Julie Miner, Christopher T. Ritchlin, Bernadette C. Siaton, Benjamin J. Smith, Abby S. Van Voorhees, A. Helena Jonsson, Amit Shah, Nancy Sullivan, Marat Turgunbaev, Laura C. Coates, Alice B. Gottlieb, Marina Magrey, W. Benjamin Nowell, Ana‐Maria Orbai, Soumya M. Reddy, José U. Scher, Evan Siegel, Michael Siegel, Jessica A. Walsh, Amy S. Turner, James Reston - Arthritis & Rheumatology 2018 cited by 481

  10. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

    Authors: Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D. Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L. Pangan, Peter Wung, In‐Ho Song - Annals of the Rheumatic Diseases 2022 cited by 124

  11. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group

    Authors: Walter P. Maksymowych, R. Lambert, Mikkel Østergaard, Susanne Juhl Pedersen, Pedro Machado, Ulrich Weber, Alexander N. Bennett, Juergen Braun, Rubén Burgos‐Vargas, Manouk de Hooge, Atul Deodhar, Iris Eshed, Anne Grethe Jurik, Kay‐Geert Hermann, Robert Landewé, Helena Marzo‐Ortega, Victoria Navarro‐Compán, Denis Poddubnyy, M. Reijnierse, Martín Rudwaleit, Joachim Sieper, Filip Van den Bosch, Désirée van der Heijde, Irene E. van der Horst‐Bruinsma, Stephanie Wichuk, Xenofon Baraliakos - Annals of the Rheumatic Diseases 2019 cited by 304

  12. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

    Authors: Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, A.M. Ellis, C. Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martín Rudwaleit, Julie Shepherd‐Smith, Tetsuya Tomita, Filip Van den Bosch, T. Vaux, Huji Xu - Annals of the Rheumatic Diseases 2023 cited by 106

  13. Treatment of axial spondyloarthritis: an update

    Authors: Abhijeet Danve, Atul Deodhar - Nature Reviews Rheumatology 2022 cited by 154

  14. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

    Authors: Atul Deodhar, P. J. Mease, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Andrew Blauvelt, C. Leonardi, Brian Porter, Ayan Das Gupta, A. Widmer, Luminita Pricop, T. Fox - Arthritis Research & Therapy 2019 cited by 293

  15. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

    Authors: Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd‐Ruediger Burmester, David Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark C. Genovese, Khalid Ahmed, Jeffrey Alper, N Barkham, Ralph E. Bennett, Francisco J. Blanco, Ricardo Blanco Alonso, Howard Blumstein, Michael S. Brooks, Gerd‐Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der‐Yuan Chen, Melvin Churchill, Christine E. Codding, Benard Combe, Peter M.G. Deane, José Del Giudice, Atul Deodhar, Rajat K. Dhar, Eva Dokoupilová, Rita M. Egan, Andrea Everding, E. Galíndez, Mark C. Genovese, David H. Goddard, Alice B. Gottlieb, Philippe Goupille, Robert Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu‐Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan Kivitz, Steven J. Klein, Mariusz Korkosz, Roshan Kotha, Joel M. Kremer, C Lue, José Luís Marenco de la Fuente, Helena Marzo‐Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama Nandagudi, Peter Nash, Antonio Fernández‐Nebro, C. Michael Neuwelt, Ana‐Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria Rell‐Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen‐Fang Tsai, Anthony Turkiewicz, L. Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielińska - The Lancet 2017 cited by 405

  16. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

    Authors: Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S. Kanik - Annals of the Rheumatic Diseases 2017 cited by 369

  17. Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

    Authors: Atul Deodhar, Lianne S. Gensler, Joachim Sieper, Michael B. Clark, César A. Calderón, Yuhua Wang, Yiying Zhou, Jocelyn H. Leu, Kim Campbell, Kristen Sweet, Diane D. Harrison, Elizabeth C. Hsia, Désirée van der Heijde - Arthritis & Rheumatology 2018 cited by 323

  18. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

    Authors: Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, C. Papavassilis, Piotr Jagiello, P. Papanastasiou, Philip J. Mease, Mark Lebwohl - Acta Dermato Venereologica 2022 cited by 94

  19. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

    Authors: Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, Philip J. Mease, Atul Deodhar, Walter P. Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H. Adams, Beth A. Pangallo, Hilde Carlier, Melvin Churchill, Kathleen P. Flint, Geoffrey Gladstein, Maria Greenwald, Mary P. Howell, Akgun Ince, Jeffrey Kaine, Daksha Mehta, Eric Peters, Roel Querubin, John D. Reveille, Richard Roseff, Roger J. Diegel, Christine Thai, Louis Bessette, Frédéric Morin, Proton Rahman, Aaron Alejandro Barrera Rodriguez, Fidencio Cons-Molina, Sergio Duran Barragan, Cassandra M. Skinner, César Pacheco‐Tena, César Ramos-Remus, Juan Cruz Rizo Rodriguez, Seung-Jae Hong, Yeon-Ah Lee, Ji Hyeon Ju, Seong Wook Kang, Tae‐Hwan Kim, Chang Keun Lee, Eun Bong Lee, Sang Heon Lee, Min‐Chan Park, Kichul Shin, Sang‐Hoon Lee, Hung-An Chen, Ying‐Chou Chen, Song‐Chou Hsieh, Joung‐Liang Lan, Zdeněk Dvořák, Radka Moravcová, Martina Malcova, Yoshinori Taniguchi, Mitsumasa Kishimoto, Kurisu Tada, Hiroaki Dobashi, Kentaro Inui, Yukitaka Ueki, Yoshifuji Matsumoto, Yoshinobu Koyama, Kazuhiro Hatta, Tatsuya Atsumi, Midori Goto, Kiyoshi Matsui, Yuya Takakubo, Gunther Neeck, Denis Poddubnyy, Andrea Rubbert‐Roth, Malgorzata Szymańska, Tomasz Blicharski, Anna Dudek, Artur Racewicz, Rafał Wojciechowski, Marleen van de Sande, E. N. Griep, Mike Nurmohamed, Galina Matsievskaya, Е. Шмидт, Marina Stanislav, S. S. Yakushin, О. Б. Ершова, А. П. Ребров, Tibor Balázs, Regina Cseuz, Edit Drescher, Gyula Poór - The Lancet 2018 cited by 359

  20. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

    Authors: Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, Walter P. Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi‐Saab, Chantal Tasset, Luc Meuleners, R. Besuyen, Thijs Hendrikx, Neelufar Mozaffarian, Ke Liu, Joy M. Greer, Atul Deodhar, Robert Landewé - The Lancet 2018 cited by 256

  21. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

    Authors: Philip J. Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Xenofon Baraliakos, Soumya D. Chakravarty, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Kristen Sweet, M. Shawi, Chetan S. Karyekar, Atul Deodhar, Désirée van der Heijde - The Lancet Rheumatology 2021 cited by 102

  22. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

    Authors: Bruce Strober, Laura C. Coates, Mark Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P. Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D. Chakravarty, Daphne Chan, M. Shawi, Ya‐Wen Yang, Diamant Thaҫi, Proton Rahman - Drug Safety 2023 cited by 55

  23. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

    Authors: Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena, Carlo Salvarani, Éric Lespessailles, Proton Rahman, Pentti A. Järvinen, Juan Sánchez‐Bursón, Karl Gaffney, Eun Bong Lee, Eswar Krishnan, Silvia Santisteban, Xiaoqi Li, Fangyi Zhao, Hilde Carlier, John D. Reveille, the COAST‐W Study Group - Arthritis & Rheumatology 2018 cited by 233

  24. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

    Authors: Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler, Tae‐Hwan Kim, Walter P. Maksymowych, Mikkel Østergaard, Denis Poddubnyy, Helena Marzo‐Ortega, Louis Bessette, Tetsuya Tomita, Ann N. Leung, Maja Hojnik, Gaia Gallo, Xiaoqi Li, David H. Adams, Hilde Carlier, Joachim Sieper, Frédéric Morin, Proton Rahman, Federico Ariel, Alberto Berman, Judith Carrio, Eleonora Lucero, José Maldonado Cocco, Rodolfo Pardo Hidalgo, Jorge Antonio Aldrete Velasco, Diego Oscar Viola, Johannes Grisar, Heinrich Resch, Clemens Scheinecker, Ana Claudia Melazzi, Luis Roimicher, Antônio Scafuto Scotton, Aaron Alejandro Barrera Rodriguez, Francisco Fidencio Cons Molina, Sergio Duran Barragan, Cassandra M. Skinner, César Pacheco‐Tena, Cesar Ricardo Ramos Remus, Juan Cruz Rizo Rodriguez, Seung‐Jae Hong, Seong Wook Kang, Chang Keun Lee, Eun Bong Lee, Sang Heon Lee, Min‐Chan Park, Sang‐Hoon Lee, Eva Dokoupilová, Zdeněk Dvořák, Martina Malcova, Karel Pvelka, Kari K. Eklund, Pentti A. Järvinen, Anna Karjalainen, Leena Paimela, Yoshinori Taniguchi, Tokutaro Tsuda, Kurisu Tada, Hiroaki Dobashi, Kentaro Inui, Yukitaka Ueki, Yoshifuji Matsumoto, Kazuhiro Hatta, Tatsuya Atsumi, Midori Goto, Shigeru Honjo, Kiyoshi Matsui, Yuya Takakubo, Gunther Neeck, Sylke Wagner, Jürgen Braun, Tomasz Blicharshi, Anna Dudek, Pawel Hrycai, Rafal Plebanski, Janina Drabiszcak-Piatkowska, Jan Brzezicki, Marek Krogulec, Daniela Opriș-Belinski, Ana Maria Ramazan, Luminita Tronaru, Marleen G. van de Sande, Galina Matsievskaya, E. A. Schmidt, Marina Stanislav, S. S. Yakushin, О. Б. Ершова, Andrey Rebroy, Melvin Churchill, Kathleen P. Flint, Maria Greenwald, Mary P. Howell, Jeffrey Kaine, Alan Kivitz, Steven J. Klein, Eric C. Mueller, Eric Peters, Roel Querubin, Michael E. Sayers, Craig D. Scoville and 17 more - The Lancet 2019 cited by 214